Want to see CATX full AI Analyst Report?
CATX Stock Chart & Stats
$4.20
-$0.13(-3.36%)
At close: 4:00 PM EST
$4.20
-$0.13(-3.36%)
Day’s Range― - ―
52-Week Range$1.96 - $6.16
Previous CloseN/A
Volume311.62K
Average Volume (3M)2.20M
Market Cap
$333.01M
Enterprise Value$165.33
Total Cash (Recent Filing)$270.93M
Total Debt (Recent Filing)$4.23M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 18, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.44
Shares Outstanding114,046,196
10 Day Avg. Volume2,191,855
30 Day Avg. Volume2,200,571
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-2.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.33Price Target Upside217.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$397.03K
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageExtremely low leverage and a sizable equity base provide durable financial flexibility to fund multi-year clinical programs and manufacturing investments. This reduces near-term refinancing risk and supports strategic optionality for partnerships or capex without immediate pressure to monetize assets.
Consistent Interim Clinical Efficacy And TolerabilityRepeated interim signals of durable responses and favorable safety across multiple 212Pb programs increase the probability of progressing to registrational studies and partnerships. Durable efficacy and tolerability are structural drivers of commercial viability and payer interest in oncology radiopharmaceuticals.
Vertically Integrated Manufacturing And Supply StrategyOwning isotope production and regional ready-to-administer manufacturing supports reliable supply, short lead times and direct-to-hospital delivery. Vertical integration can create a sustainable competitive moat, reduce COGS volatility and enable faster commercial scale-up once approvals are secured.
Bears Say
High Cash Burn And Negative Cash FlowSustained negative operating and free cash flow will steadily deplete cash reserves absent revenue or new financing. Persistent burn pressures strategic choices, increases refinancing dependency, and can force trade-offs between R&D, manufacturing scale-up, and commercialization timelines.
Minimal Current Revenue And Deeply Negative MarginsWith negligible revenue and large operating losses, the company has limited internal runway to fund commercialization. Negative margins reflect high fixed costs relative to an early-stage revenue base, making sustainable profitability contingent on successful product approvals and material revenue scale-up.
Early-stage Clinical And Commercialization Execution RiskKey programs remain in Phase 1/2a with dose escalation and follow-up ongoing; regulatory approval, payer acceptance and large-scale hospital adoption are uncertain. Execution risk across trials, manufacturing scale-up and market access remains a structural hurdle to translating clinical promise into durable revenue.
Perspective Therapeutics News
CATX FAQ
What was Perspective Therapeutics, Inc.’s price range in the past 12 months?
Perspective Therapeutics, Inc. lowest stock price was $1.96 and its highest was $6.16 in the past 12 months.
What is Perspective Therapeutics, Inc.’s market cap?
Perspective Therapeutics, Inc.’s market cap is $333.01M.
When is Perspective Therapeutics, Inc.’s upcoming earnings report date?
Perspective Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 27 days.
How were Perspective Therapeutics, Inc.’s earnings last quarter?
Perspective Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.044.
Is Perspective Therapeutics, Inc. overvalued?
According to Wall Street analysts Perspective Therapeutics, Inc.’s price is currently Undervalued.
Does Perspective Therapeutics, Inc. pay dividends?
Perspective Therapeutics, Inc. does not currently pay dividends.
What is Perspective Therapeutics, Inc.’s EPS estimate?
Perspective Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Perspective Therapeutics, Inc. have?
Perspective Therapeutics, Inc. has 114,046,196 shares outstanding.
What happened to Perspective Therapeutics, Inc.’s price movement after its last earnings report?
Perspective Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of Perspective Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Perspective Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (217.46% Upside)
$13.33 (217.46% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 80.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.72%
Trailing 12-Months
Company Description
Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
CATX Stock 12 Month Forecast
Average Price Target
$13.33
▲(217.46% Upside)
Technical Analysis
Ownership Overview
1.63% Insiders
6.91% Mutual Funds
0.08% Other Institutional Investors
78.13% Public Companies and
Individual Investors